MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...
After starting my career at PCMag as an intern more than a decade ago, I’m back as one of its editors, focused on managing laptops, desktops, and components coverage. With 15 years of experience, I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback